Skip to main content

Table 5 Treatment benefit according to PREDICT model versus risk of recurrence score for patients with HR+/HER2− pT1pN0 disease

From: Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

 

PREDICT model (absolute benefit of chemotherapy, 10-year OS)

 

< 3%

3–5%

≥ 5%

No. of patients

ROR score

    

 Low

57

30

0

87

 Intermediate, Luminal A

8

18

2

16

 Intermediate, Luminal B

4

12

3

19

 High

2

12

14

28

Total

71

72

19

162

  1. Abbreviations: HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, OS Overall survival, ROR Risk of recurrence
  2. Ki-67 positivity for the PREDICT model (http://www.predict.nhs.uk/) is defined as > 10% of tumor cells staining positive (average counting). Adjusting for Ki-67 labeling index as a hot spot in our study, Ki-67 positivity for the PREDICT analysis was defined as > 20% of tumor cells staining positive [46]